Management of bevacizumab-associated bowel perforation: A case series and review of the literature

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 577-582

  Badgwell, B D ^a   Camp, E R ^a   Feig, B ^a   Wolff, R A ^a   Eng, C ^a   Ellis, L M ^a   Cormier, J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Avastin; Bevacizumab; Complication; GI perforation; Toxicity

Indexed keywords

BEVACIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ARTICLE; CANCER CHEMOTHERAPY; CATHETERIZATION; COLORECTAL CARCINOMA; DIVERTICULOSIS; ESOPHAGUS CARCINOMA; FEVER; HUMAN; HYPOTENSION; INCIDENCE; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEUKOCYTOSIS; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA AND VOMITING; NEOPLASM; OVARY CARCINOMA; PANCREAS CARCINOMA; PEPTIC ULCER; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; STOMACH CANCER; SYMPTOMATOLOGY; TACHYCARDIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INCIDENCE; INTESTINAL PERFORATION; NEOPLASM METASTASIS; NEOPLASMS; SURVIVAL RATE;

EID: 40149096054     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm508     Document Type: Article

References (23)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335-2342.
2. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25 (12): 1539-1544.
3. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24): 2542-2550.
4. Yang JC, Haworth L, Sherry RM et al. A randomized-trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349 (5): 427-434.
5. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11): 2184-2191.
6. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23 (4): 792-799.
7. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23 (31): 8033-8040.
8. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: Metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005; 69 (Suppl 3): 46-56.
9. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246 (4935): 1309-1312.
10. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246 (4935): 1306-1309.
11. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69 (Suppl 3): 25-33.
12. Lordick F, Geinitz H, Theisen J et al. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three cases. Int J Radiat Oncol Biol Phys 2006; 64 (5): 1295-1298.
13. Hedrick E, Kozloff M, Hainsworth J et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE) [meeting abstracts]. J Clin Oncol 2006; 24 (18 Suppl): (Abstr 3536).
14. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23 (16): 3697-3705.
15. Sugrue M, Kozloff M, Hainsworth J et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy [meeting abstracts]. J Clin Oncol 2006; 24 (18 Suppl): (Abstr 3535).
16. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31 (4): 1250-1256.
17. Chen HX, Mooney M, Boron M et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24 (21): 3354-3360.
18. Crane CH, Ellis LM, Abbruzzese JL et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006; 24 (7): 1145-1151.
19. Wright JD, Hagemann A, Rader JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006; 107 (1): 83-89.
20. Genentech Press-Release from 9/23/05 http://www.gene.com/gene/news/ press-releases/index.jsp2 January 2007, date last accessed).
21. Mularski RA, Sippel JM, Osborne ML. Pneumoperitoneum: A review of nonsurgical causes. Crit Care Med 2000; 28 (7): 2638-2644.
22. Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91 (3): 173-180.
23. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: Incidence, etiology, and management. Curr Surg 2006; 63 (5): 334-337.